Pentaerythrityltetranitrate (PETN) improves utero- and feto-placental Doppler parameters in pregnancies with impaired utero-placental perfusion in mid-gestation – a secondary analysis of the PETN-pilot trial

References

[1] Gluckman PD, Hanson MA, Cooper C, Thornburg KL. Effect of in utero and early-life conditions on adult health and disease. N Engl J Med. 2008;359:61–73.10.1056/NEJMra0708473Search in Google Scholar PubMed PubMed Central

[2] Gardosi J. Intrauterine growth restriction: new standards for assessing adverse outcome. Best Pract Res Clin Obstet Gynaecol. 2009;23:741–9.10.1016/j.bpobgyn.2009.09.001Search in Google Scholar PubMed

[3] Heazell AE, Worton SA, Higgins LE, Ingram E, Johnstone ED, Jones RL, et al. IFPA Gabor Than Award Lecture: recognition of placental failure is key to saving babies’ lives. Placenta. 2015;36 Suppl 1:S20–8.10.1016/j.placenta.2014.12.017Search in Google Scholar PubMed

[4] Stott D, Bolten M, Salman M, Paraschiv D, Clark K, Kametas NA. Maternal demographics and hemodynamics for the prediction of fetal growth restriction at booking, in pregnancies at high risk for placental insufficiency. Acta Obstet Gynecol Scand. 2016;95:329–38.10.1111/aogs.12823Search in Google Scholar PubMed

[5] Ventura W, De Paco Matallana C, Prieto-Sanchez MT, Macizo MI, Pertegal M, Nieto A, et al. Uterine and umbilical artery Doppler at 28 weeks for predicting adverse pregnancy outcomes in women with abnormal uterine artery Doppler findings in the early second trimester. Prenat Diagn. 2015;35:294–8.10.1002/pd.4542Search in Google Scholar PubMed

[6] Friedman AM, Cleary KL. Prediction and prevention of ischemic placental disease. Semin Perinatol. 2014;38:177–82.10.1053/j.semperi.2014.03.002Search in Google Scholar PubMed

[7] Kleinrouweler CE, Bossuyt PM, Thilaganathan B, Vollebregt KC, Arenas Ramirez J, Ohkuchi A, et al. Value of adding second-trimester uterine artery Doppler to patient characteristics in identification of nulliparous women at increased risk for pre-eclampsia: an individual patient data meta-analysis. Ultrasound Obstet Gynecol. 2013;42:257–67.10.1002/uog.12435Search in Google Scholar PubMed

[8] Lees CC, Marlow N, van Wassenaer-Leemhuis A, Arabin B, Bilardo CM, Brezinka C, et al. 2 year neurodevelopmental and intermediate perinatal outcomes in infants with very preterm fetal growth restriction (TRUFFLE): a randomised trial. Lancet. 2015;385:2162–72.10.1016/S0140-6736(14)62049-3Search in Google Scholar PubMed

[9] D’Souza R, Keating S, Walker M, Drewlo S, Kingdom J. Unfractionated heparin and placental pathology in high-risk pregnancies: secondary analysis of a pilot randomized controlled trial. Placenta. 2014;35:816–23.10.1016/j.placenta.2014.07.010Search in Google Scholar PubMed

[10] Morris RK, Oliver EA, Malin G, Khan KS, Meads C. Effectiveness of interventions for the prevention of small-for-gestational age fetuses and perinatal mortality: a review of systematic reviews. Acta Obstet Gynecol Scand. 2013;92:143–51.10.1111/aogs.12029Search in Google Scholar PubMed

[11] Abheiden C, Van Hoorn ME, Hague WM, Kostense PJ, van Pampus MG, Vries JI. Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial Doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results. Br J Obstet Gynaecol. 2016;123:797–805.10.1111/1471-0528.13421Search in Google Scholar PubMed

[12] Dodd JM, McLeod A, Windrim RC, Kingdom J. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database Syst Rev. 2013;7:CD006780.10.1002/14651858.CD006780.pub3Search in Google Scholar PubMed

[13] Henderson JT, Whitlock EP, O’Connor E, Senger CA, Thompson JH, Rowland MG. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2014;160:695–703.10.7326/M13-2844Search in Google Scholar PubMed

[14] Lesmes C, Gallo DM, Panaiotova J, Poon LC, Nicolaides KH. Prediction of small-for-gestational-age neonates: screening by fetal biometry at 19–24 weeks. Ultrasound Obstet Gynecol. 2015;46:198–207.10.1002/uog.14826Search in Google Scholar PubMed

[15] Sovio U, White IR, Dacey A, Pasupathy D, Smith GC. Screening for fetal growth restriction with universal third trimester ultrasonography in nulliparous women in the pregnancy outcome prediction (POP) study: a prospective cohort study. Lancet. 2015;386:2089–97.10.1097/OGX.0000000000000305Search in Google Scholar

[16] Daiber A, Wenzel P, Oelze M, Munzel T. New insights into bioactivation of organic nitrates, nitrate tolerance and cross-tolerance. Clin Res Cardiol. 2008;97:12–20.10.1007/s00392-007-0588-7Search in Google Scholar PubMed

[17] Kinderlerer AR, Pombo Gregoire I, Hamdulay SS, Ali F, Steinberg R, Silva G, et al. Heme oxygenase-1 expression enhances vascular endothelial resistance to complement-mediated injury through induction of decay-accelerating factor: a role for increased bilirubin and ferritin. Blood. 2009;113:1598–607.10.1182/blood-2008-04-152934Search in Google Scholar PubMed

[18] Oppermann M, Balz V, Adams V, Dao VT, Bas M, Suvorava T, et al. Pharmacological induction of vascular extracellular superoxide dismutase expression in vivo. J Cell Mol Med. 2009;13:1271–8.10.1111/j.1582-4934.2008.00627.xSearch in Google Scholar PubMed PubMed Central

[19] Schleussner E, Lehmann T, Kahler C, Schneider U, Schlembach D, Groten T. Impact of the nitric oxide-donor pentaerythrityl-tetranitrate on perinatal outcome in risk pregnancies: a prospective, randomized, double-blinded trial. J Perinat Med. 2014;42:507–14.10.1515/jpm-2013-0212Search in Google Scholar PubMed

[20] Bhide A, Acharya G, Bilardo CM, Brezinka C, Cafici D, Hernandez-Andrade E, et al. ISUOG practice guidelines: use of Doppler ultrasonography in obstetrics. Ultrasound Obstet Gynecol. 2013;41:233–9.10.1002/uog.12371Search in Google Scholar PubMed

[21] Baschat AA, Gembruch U. The cerebroplacental Doppler ratio revisited. Ultrasound Obstet Gynecol. 2003;21:124–7.10.1002/uog.20Search in Google Scholar PubMed

[22] Gramellini DD. Cerebral-umbilical Doppler ratio as a predictor of adverse perinatal outcome. Obstet Gynecol. 1992;79: 416–20.10.1097/00006250-199203000-00018Search in Google Scholar PubMed

[23] Odibo AO, Riddick C, Pare E, Stamilio DM, Macones GA. Cerebroplacental Doppler ratio and adverse perinatal outcomes in intrauterine growth restriction: evaluating the impact of using gestational age–specific reference values. J Ultrasound Med. 2005;24:1223–8.10.7863/jum.2005.24.9.1223Search in Google Scholar PubMed

[24] DeVore GR. The importance of the cerebroplacental ratio in the evaluation of fetal well-being in SGA and AGA fetuses. Am J Obstet Gynecol. 2015;213:5–15.10.1016/j.ajog.2015.05.024Search in Google Scholar PubMed

[25] Kurmanavicius J, Florio I, Wisser J, Hebisch G, Zimmermann R, Müller R, et al. Reference resistance indices of the umbilical, fetal middle cerebral and uterine arteries at 24–42 weeks of gestation. Ultrasound Obstet Gynecol. 1997;10:112–20.10.1046/j.1469-0705.1997.10020112.xSearch in Google Scholar PubMed

[26] Lees C, Valensise H, Black R, Harrington K, Byiers S, Romanini C. The efficacy and fetal-maternal cardiovascular effects of transdermal glyceryl trinitrate in the prophylaxis of pre-eclampsia and its complications: a randomized double-blind placebo-controlled trial. Ultrasound Obstet Gynecol. 1998;12:334–8.10.1046/j.1469-0705.1998.12050334.xSearch in Google Scholar PubMed

[27] Dunn L, Greer R, Flenady V, Kumar S. Sildenafil in pregnancy: a systematic review of maternal tolerance and obstetric and perinatal outcomes. Fetal Diagn Ther. 2017;41:81–8.10.1159/000453062Search in Google Scholar PubMed

[28] Trapani A, Gonçalves LF, Trapani TF, Franco MJ, Galluzzo RN, Pires MM. Comparison between transdermal nitroglycerin and sildenafil citrate in intrauterine growth restriction: effects on uterine, umbilical and fetal middle cerebral artery pulsatility indices. Ultrasound Obstet Gynecol. 2016;48:61–5.10.1002/uog.15673Search in Google Scholar PubMed

[29] Ganzevoort W, Alfirevic Z, von Dadelszen P, Kenny L, Papageorghiou A, van Wassenaer-Leemhuis A, et al. Strider: sildenafil therapy in dismal prognosis early-onset intrauterine growth restriction – a protocol for a systematic review with individual participant data and aggregate data meta-analysis and trial sequential analysis. Syst Rev. 2014;3:23.10.1186/2046-4053-3-23Search in Google Scholar PubMed PubMed Central

[30] Bujold E. Low-dose aspirin reduces morbidity and mortality in pregnant women at high-risk for preeclampsia. Evid Based Nurs. 2015;18:71.10.1136/ebnurs-2014-101915Search in Google Scholar PubMed

[31] Bujold E, Roberge S, Nicolaides KH. Low-dose aspirin for prevention of adverse outcomes related to abnormal placentation. Prenat Diagn. 2014;34:642–8.10.1002/pd.4403Search in Google Scholar PubMed

[32] Rolnik DL, Wright D, Poon LC, O’Gorman N, Syngelaki A, de Paco Matallana C, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377:613–22.10.1056/NEJMoa1704559Search in Google Scholar PubMed